Biostate AI and Weill Cornell Medicine Collaborate to Develop AI Models for Personalized Leukemia Care [Yahoo! Finance]
10x Genomics, Inc. (TXG)
Last 10x genomics, inc. earnings: 2/18 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Cornell Medicine have entered into a strategic collaboration to develop AI for personalized assessments of patient disease prognosis and evolution. Initially, the collaboration will focus on leukemia, leveraging the Weill Cornell Leukemia Program's vast biorepository of bone marrow and blood samples. Under the agreement, Biostate AI will leverage its proprietary barcode-integrated reverse transcription (BIRT) technology for RNA sequencing (RNAseq) to analyze RNA expression from patient samples at scale. These results will be used to pre-train and fine-tune a transformer-based AI model, using RNA expression as its "language." Together, Biostate AI and Weill Cornell Medicine will look to prototype and then validate an AI model that will be able to perform acute myeloid leukemia (AML) subtype stratification, disease prognosis, and therapy selection. "Current personalized medicine approaches look only at one or a few key biomarkers for each disease," said David Zhang , co-founder and
Show less
Read more
Impact Snapshot
Event Time:
TXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXG alerts
High impacting 10x Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
TXG
News
- 10x Genomics (NASDAQ:TXG) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Barclays Turns More Bullish on 10x Genomics, Inc. (TXG) Despite Uneven Research Spending [Yahoo! Finance]Yahoo! Finance
- 10x Genomics (NASDAQ:TXG) had its price target raised by analysts at Canaccord Genuity Group Inc. from $19.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- 10x Genomics (NASDAQ:TXG) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- 10x Genomics (NASDAQ:TXG) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "cautious" rating.MarketBeat
TXG
Earnings
- 11/6/25 - Beat
TXG
Sec Filings
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- TXG's page on the SEC website